Journal of mucopolysaccharidosis and rare diseases

Association for Research of MPS and Rare Diseases (뮤코다당증연구학회)
권호 표지
DOI QR코드

DOI QR Code

Overview of Mucolipidosis Type II and Mucolipidosis Type III α/β

  • Kim, Su Jin (Department of Pediatrics, Myongji Hospital, Seonam University College of Medicine)
  • Received : 2016.06.10
  • Accepted : 2016.06.18
  • Published : 2016.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Mucolipidosis type II (MLII; MIM#252500) and type III alpha/beta (MLIIIA; MIM#252600) very rare lysosomal storage disease cause by reduced enzyme activity of GlcNAc-1-phosphotransferase. ML II is caused by a total or near total loss of GlcNAc-1-phosphotransferase activity whether enzymatic activity in patient with ML IIIA is reduced. While ML II and ML III share similar clinical features, including skeletal abnormalities, ML II is the more severe in terms of phenotype. ML III is a much milder disorder, being characterized by latter onset of clinical symptoms and slower progressive course. GlcNAc-1-phosphotransferase is encoded by two genes, GNPTAB and GNPTG, mutations in GNPTAB give rise to ML II or ML IIIA. To date, more than 100 different GNPTAB mutations have been reported, causing either ML II or ML IIIA. Despite development of new diagnostic approach and understanding of disease mechanism, there is no specific treatment available for patients with ML II and ML IIIA yet, only supportive and symptomatic treatment is indicated.

Keywords

References

  1. Okada S, Owada M, Sakiyama T, Yutaka T, Ogawa M. Icell disease: clinical studies of 21 Japanese cases. Clin Genet 1985;28:207-15.
  2. Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 2004;12:87-92. https://doi.org/10.1038/sj.ejhg.5201044
  3. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-6. https://doi.org/10.1007/s004399900075
  4. Leroy JG, Demars RI. Mutant enzymatic and cytological phenotypes in cultured human fibroblasts. Science 1967;157:804-6. https://doi.org/10.1126/science.157.3790.804
  5. Maroteaux P, Hors-Cayla MC, Pont J. Type II mucolipidosis. Presse Med 1970;78:179-81.
  6. Walbaum R, Dehaene P, Scharfman W, Farriaux JP, Tondeur M, Vamos-Hurwitz E, et al. Mucolipidosis of type II (I-cell disease): study of 3 cases. Arch Fr Pediatr 1972;29:895.
  7. Matalon R, Cifonelli JA, Zellweger H, Dormanfman A. Lipid abnormalities in a variant of the Hurler syndrome. Proc Natl Acad Sci U S A 1968;59:1097-102. https://doi.org/10.1073/pnas.59.4.1097
  8. Maroteaux P, Lamy M. Hurler's pseudo-polydystrophy. Presse Med 1966;74:2889-92.
  9. Cathey SS, Leroy JG, Wood T, Eaves K, Simensen RJ, Kudo M, et al. Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands. J Med Genet 2010;47:38-48. https://doi.org/10.1136/jmg.2009.067736
  10. Gilbert-Barness EF, Barness LA. The mucolipidoses. Perspect Pediatr Pathol 1993;17:148-84.
  11. Smuts I, Potgieter D, van der Westhuizen FH. Combined tarsal and carpal tunnel syndrome in mucolipidosis type III. A case study and review. Ann N Y Acad Sci 2009;1151:77-84. https://doi.org/10.1111/j.1749-6632.2008.03451.x
  12. Dierks T, Schlotawa L, Frese MA, Radhakrishnan K, von Figura K, Schmidt B. Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann-Pick C1 disease - Lysosomal storage disorders caused by defects of nonlysosomal proteins. Biochim Biophys Acta 2009;1793:710-25. https://doi.org/10.1016/j.bbamcr.2008.11.015
  13. Kornfeld SS, W. The Metabolic and Molecular Basis of Inherited Disease.: McGraw-Hill 2001:3469-82.
  14. Reitman ML, Kornfeld S. Lysosomal enzyme targeting. N-Acetylglucosaminylphosphotransferase selectively phosphorylates native lysosomal enzymes. J Biol Chem 1981;256:11977-80.
  15. Waheed A, Hasilik A, von Figura K. UDP-N-acetylglucosamine: lysosomal enzyme precursor N-acetylglucosamine- 1-phosphotransferase. Partial purification and characterization of the rat liver Golgi enzyme. J Biol Chem 1982;257:12322-31.
  16. Varki A, Reitman ML, Vannier A, Kornfeld S, Grubb JH, Sly WS. Demonstration of the heterozygous state for I-cell disease and pseudo-Hurler polydystrophy by assay of Nacetylglucosaminylphosphotransferase in white blood cells and fibroblasts. Am J Hum Genet 1982;34:717-29.
  17. Waheed A, Hasilik A, von Figura K. Processing of the phosphorylated recognition marker in lysosomal enzymes. Characterization and partial purification of a microsomal alpha- N-acetylglucosaminyl phosphodiesterase. J Biol Chem 1981;256:5717-21.
  18. Bao M, Booth JL, Elmendorf BJ, Canfield WM. Bovine UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine- 1-phosphotransferase. I. Purification and subunit structure. J Biol Chem 1996;271:31437-45. https://doi.org/10.1074/jbc.271.49.31437
  19. Raas-Rothschild A, Cormier-Daire V, Bao M, Genin E, Salomon R, Brewer K, et al. Molecular basis of variant pseudohurler polydystrophy (mucolipidosis IIIC). J Clin Invest 2000;105:673-81. https://doi.org/10.1172/JCI5826
  20. Kudo M, Bao M, D'Souza A, Ying F, Pan H, Roe BA, et al. The alpha- and beta-subunits of the human UDP-Nacetylglucosamine: lysosomal enzyme N-acetylglucosamine-1-phosphotransferase [corrected] are encoded by a single cDNA. J Biol Chem 2005;280:36141-9. https://doi.org/10.1074/jbc.M509008200
  21. Varki AP, Reitman ML, Kornfeld S. Identification of a variant of mucolipidosis III (pseudo-Hurler polydystrophy): a catalytically active N-acetylglucosaminylphosphotransferase that fails to phosphorylate lysosomal enzymes. Proc Natl Acad Sci U S A 1981;78:7773-7. https://doi.org/10.1073/pnas.78.12.7773
  22. Kollmann K, Pohl S, Marschner K, Encarnacao M, Sakwa I, Tiede S, et al. Mannose phosphorylation in health and disease. Eur J Cell Biol 2010;89:117-23. https://doi.org/10.1016/j.ejcb.2009.10.008
  23. Afshar A. Bilateral carpal tunnel syndrome and multiple trigger fingers in a child with mucolipidosis Type III disease. Indian J Plast Surg 2011;44:517-20. https://doi.org/10.4103/0970-0358.90845
  24. Hetherington C, Harris NJ, Smith TW. Orthopaedic management in four cases of mucolipidosis type III. J R Soc Med 1999;92:244-6. https://doi.org/10.1177/014107689909200508
  25. Haddad FS, Hill RA, Vellodi A. Orthopaedic manifestations of mucolipidosis III: an illustrative case. J Pediatr Orthop B 2000;9:58-61. https://doi.org/10.1097/01202412-200001000-00014
  26. Robinson C, Baker N, Noble J, King A, David G, Sillence D, et al. The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment. J Inherit Metab Dis 2002;25:681-93. https://doi.org/10.1023/A:1022935115323
  27. Lewis JR, Gibson PH. Bilateral hip replacement in three patients with lysosomal storage disease: Mucopolysaccharidosis type IV and Mucolipidosis type III. J Bone Joint Surg Br 2010;92:289-92.
  28. Leroy JG, Cathey SS, Friez MJ. $GeneReviews^{(R)}$ [Internet]: University of Washington, 2008.
  29. Mallen J, Highstein M, Smith L, Cheng J. Airway management considerations in children with I-cell disease. Int J Pediatr Otorhinolaryngol 2015;79:760-2. https://doi.org/10.1016/j.ijporl.2015.02.034
  30. Ishak M, Zambrano EV, Bazzy-Asaad A, Esquibies AE. Unusual pulmonary findings in mucolipidosis II. Pediatr Pulmonol 2012;47:719-21. https://doi.org/10.1002/ppul.21599
  31. Lund TC, Cathey SS, Miller WP, Eapen M, Andreansky M, Dvorak CC, et al. Outcomes after hematopoietic stem cell transplantation for children with I-cell disease. Biol Blood Marrow Transplant 2014;20:1847-51. https://doi.org/10.1016/j.bbmt.2014.06.019
  32. Shibazaki T, Hirabayashi K, Saito S, Shigemura T, Nakazawa Y, Sakashita K, et al. Clinical and laboratory outcomes after umbilical cord blood transplantation in a patient with mucolipidosis II alpha/beta. Am J Med Genet A 2016;170A:1278-82.